Executive turnover reflects changing drug industry

11/1/2007 | Financial Times (free content)

The appointment of new chief executives at GlaxoSmithKline, Sanofi-Aventis and other major drug companies indicates that big pharma is struggling to recover from slumping valuations and competition from generics. Firms are also tapping young leaders, focusing on the international market, appointing executives with little background in research and development, and selecting from within rather than recruiting outside executives.

View Full Article in:

Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide